
    
      All eligible patients will be equally randomized between the 2 following treatment groups:

      Standard treatment group: Camrelizumab 200mg IV every 2 weeks. Experimental group:
      Stereotactic body radiotherapy 27Gy/3F and Camrelizumab 200mg IV every 2 weeks.
    
  